局部晚期头颈部鳞状细胞癌中的癌症干细胞生物标志物

Cancer stem cell biomarkers in locally advanced head and neck squamous cell carcinoma.

作者信息

Caballero-Borrego Miguel, Grau Juan J, Basté Neus, Castillo Paola C, Teixido Cristina, Valduvieco Izaskun, Vilaseca Isabel

机构信息

Hospital Clinic of Barcelona, Otolaryngology Department, Barcelona, Spain; Universitat de Barcelona, Facultat de Medicina i Ciències de la Salut, Department of Surgery and Medical-Surgical Specialties, Barcelona, Spain; Institut d'Investigacions Biomèdiques Agusti Pi Sunyer (IDIBAPS), Barcelona, Spain.

Hospital Clínic, Department of Medical Oncology, Barcelona, Spain.

出版信息

Braz J Otorhinolaryngol. 2025 Jul 29;91(6):101689. doi: 10.1016/j.bjorl.2025.101689.

DOI:10.1016/j.bjorl.2025.101689

PMID:40738059

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12329299/

Abstract

OBJECTIVES

To analyze the presence of cancer stem cells markers in consecutive patients with locally advanced Head and Neck Squamous Cell Carcinoma (HNSCC) and establish their suitability as a prognostic biomarker in samples from routine practice.

METHODS

Retrospective study of 104 consecutive patients with locally advanced HNSCC treated with definitive surgery and adjuvant chemoradiotherapy. Immunohistochemical expression of CD44, HLA-I, pan-cytokeratin, and phosphorylated Epidermal Growth Factor Receptor (p-EGFR) were evaluated in surgical specimens. Overall Survival (OS) and Disease-Free Survival (DFS) rates were calculated based on clinical characteristics and the total positive score (for tumor marker expression). Hazard ratios were calculated by Cox multivariate analysis.

RESULTS

After a median follow-up of 50-months, higher OS rates were observed for patients without cervical node pathological involvement (p < 0.001), patients with HLA-I overexpression and a total positive score ≥ 15% (p = 0.017), and patients with low CD44 expression and a total positive score ≤ 60% (p = 0.022). Grouping by p-EGFR (p = 0.648) or pan-cytokeratin (p = 0.477) expression did not show statistical differences in OS. None of the biomarkers were associated with different DFS rates. Cox multivariate analysis revealed that positive cervical nodes (HR = 1.294; 95% CI 1.025-1.634; p = 0.030) and the expressions of HLA (HR = 0.373; 95% CI 0.168‒0.829; p = 0.015) and CD44 (HR = 2.170; 95% CI 1.031-4.569; p = 0.041) were independently associated with OS.

CONCLUSION

Nodal involvement, HLA-I overexpression, and decreased CD44 expression are independent prognostic factors of survival in patients with locally advanced HNSCC.

LEVEL OF EVIDENCE

III.

摘要

目的

分析局部晚期头颈部鳞状细胞癌（HNSCC）连续患者中癌症干细胞标志物的存在情况，并确定其在常规实践样本中作为预后生物标志物的适用性。

方法

对104例接受根治性手术和辅助放化疗的局部晚期HNSCC连续患者进行回顾性研究。评估手术标本中CD44、HLA-I、全细胞角蛋白和磷酸化表皮生长因子受体（p-EGFR）的免疫组化表达。根据临床特征和总阳性评分（肿瘤标志物表达）计算总生存期（OS）和无病生存期（DFS）率。通过Cox多因素分析计算风险比。

结果

中位随访50个月后，无颈淋巴结病理受累的患者（p < 0.001）、HLA-I过表达且总阳性评分≥15%的患者（p = 0.017）以及CD44低表达且总阳性评分≤60%的患者（p = 0.022）的OS率较高。按p-EGFR（p = 0.648）或全细胞角蛋白（p = 0.477）表达分组在OS方面未显示统计学差异。没有一种生物标志物与不同的DFS率相关。Cox多因素分析显示，阳性颈淋巴结（HR = 1.294；95%CI 1.025 - 1.634；p = 0.030）以及HLA（HR = 0.373；95%CI 0.168 - 0.